Nanoregmed Ltd
Registered name: NANOREGMED LTD
Nanoregmed Ltd does not publish its revenue or profit. Its accounts to 30 Jun 2025 show net assets of £15.4k and 1 employee.
Nanoregmed Ltd did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 30 Jun 2025 showed net assets of £15.4k and 1 employee. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 12 yrs · since 2014
- Type
- Private Limited Company
Key figures
Revenue not disclosed
Nanoregmed Ltd’s accounts for the year to 30 Jun 2025 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 1
- Net assets
- £15.4k
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Jun 2022 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | No P&L |
| Profit & loss | ||||
| Revenue (turnover) | £50.5k | £35.2k | £57.6k | — |
| Profit after tax | £23k | −£14.4k | −£5.9k | — |
| Profit (best available) | £23k | −£14.4k | −£5.9k | — |
| Staff costs | £4.3k | £4.3k | £15.7k | — |
| Employees (average) | — | 1 | 2 | 1 |
| Ratios | ||||
| Profit margin | 45.5% | −41% | −10.2% | — |
| Revenue per employee | — | £35.2k | £28.8k | — |
| Profit per employee | — | −£14.4k | −£2.9k | — |
| Growth (year on year) | ||||
| Revenue growth | — | ▼30.3% | ▲63.6% | — |
| Profit growth | — | ▼162.8% | — | — |
| Headcount growth | — | — | ▲100% | ▼50% |
| Balance sheet — indirect signals, not revenue | ||||
| Net assets | £57k | £48.7k | £42.8k | £15.4k |
| Fixed assets | £1.7k | £2k | £1.5k | £1.1k |
| Current assets | £60.3k | £46.9k | £46k | £8.2k |
| Source | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Apr 2025 | FullAccounts · bulk data Mar 2026 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼64%
- Now £15.4k
- Cash at bank
- —
- Now —
- Headcount
- ▼50%
- Now 1
- Deferred income
- —
- Now —
- Fixed assets
- ▼27%
- Now £1.1k
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 30 Jun 2025, from the Companies House accounts bulk data published Mar 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.